<DOC>
	<DOCNO>NCT01190735</DOCNO>
	<brief_summary>Numerous epidemiological study link lifelong use caffeine low risk Parkinson 's disease ( PD ) - prospective study estimate non-coffee drinker approximately 1.7-2.5 fold increase risk develop PD compare coffee drinker . This extremely important find deserves depth investigation . The exact pathophysiological mechanism remain elusive , multiple hypothesis exist : Caffeine antagonize adenosine receptor directly yield improvement motor system even Levodopa serum concentration ( therapy ) . An additional explanation adenosine antagonism neuroprotective property act locally basal ganglia circuit substantia nigra . The current study aim identify optimal caffeine dose maximal motor benefit least amount undesirable adverse effect .</brief_summary>
	<brief_title>Caffeine Motor Manifestations Parkinson 's Disease</brief_title>
	<detailed_description>Caffeine widespread use century , commonest psychostimulant use worldwide . In Canada , estimate mean daily intake 70 kg person range 200-450 mg . The main source caffeine ingestion beverage - depend brewing technique typical cup drip-filtered coffee contain 100 150 mg caffeine ( gourmet drip coffee contain 300 mg espresso preparation generally contain much less caffeine ) . Black tea contain 30 50 mg , low amount caffeine find soft drink , green tea , chocolate . Caffeine substance well-defined effect side-effect profile , general well tolerate . Side effect include irritability , insomnia , enhancement physiologic tremor , stomach upset . Abrupt withdrawal caffeine cause headache excessive sleepiness . Caffeine exacerbate pre-existing supraventricular tachycardia . Multiple large-scale epidemiologic study find evidence adverse health effect long-term moderate use caffeine . Caffeine T-max approximately 1 hour readily cross blood brain barrier . It first order kinetics . Plasma half life estimate range 3-6 hour , increase case pregnancy severe liver disease . Drug interaction uncommon : Caffeine withdrawal may cause lithium toxicity , caffeine increase clozapine level . CNS effect caffeine mainly due antagonism A1 A2A adenosine receptor , ( A2A predominate striatum ) . Potential effect upon motor manifestation PD predominantly relate antagonistic action adenosine dopamine release striatum . Partial tolerance CNS effect common , begin occur within one week ( tolerance pronounce A1 receptor , suggest motor change may show less tolerance ) . If effective PD , caffeine potential important advance patient care , numerous reason . First , widespread use century , long-term safety determine . Caffeine widely available tablet inexpensive ( i.e . le 25 cent per tablet ) , potentially result substantial cost saving patient health-care planner . Caffeine also potential ( yet unproven ) treat non-motor manifestation PD , particularly excessive daytime somnolence .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Central Nervous System Stimulants</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1 . Subject diagnose idiopathic Parkinson 's disease ( stage I IV Hoehn Yahr ) 1 . Estimated daily caffeine intake 200 mg per day . 2 . Subject dementia ( MMSE &lt; 26/30 ) ADL impairment secondary cognitive loss , inability understand consent process . 3 . Changes antiparkinsonian medication last 4 week change require period study protocol . 4 . Contraindication caffeine use : 1 . Uncontrolled hypertension ( systolic bp &gt; 170 diastolic bp &gt; 110 two consecutive reading ) 2 . Use lithium clozapine 3 . Premenopausal woman use effective method birth control 4 . Current use prescribe alert agent modafinil methylphenidate 5 . Active peptic ulcer disease 6 . Supraventricular cardiac arrhythmia 7 . Previous adverse reaction caffeine either required admission hospital , patient directly advise physician use caffeine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Caffeine</keyword>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Parkinson Disease</keyword>
	<keyword>Parkinsonian Disorders</keyword>
	<keyword>Basal Ganglia Diseases</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Movement Disorders</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Caffeine citrate</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Central Nervous System Stimulants</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Central Nervous System Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
</DOC>